Development and evaluation of age-appropriate film-coated tablets of levamisole for paediatric use (2-18 years)

Expert Opinion on Drug Delivery

Volumn 10, Issue 3, 2013, Pages 293-300

  Kreeftmeijer Vegter, Annemarie Rosan ^a   De Meijer, Mariska ^a   Wegman, Kim Am ^a   Van Veldhuizen, Cees Kw ^a  

^a ACE Pharmaceuticals BV   (Netherlands)

Author keywords

Film coated tablets; Levamisole; Nephrotic syndrome; Paediatric formulation; Suitability

Indexed keywords

LEVAMISOLE;

ADOLESCENT; ADULT; ARTICLE; BITTER TASTE; CHILD; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FILM COATING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MASKING; NEPHROTIC SYNDROME; PALATABILITY; PEDIATRICS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SCHOOL CHILD; SWALLOWING; TABLET FORMULATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADOLESCENT; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; DEGLUTITION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMPOUNDING; DRUG EVALUATION; HUMANS; LEVAMISOLE; NEPHROTIC SYNDROME; TABLETS; TABLETS, ENTERIC-COATED; TASTE PERCEPTION;

EID: 84873912550     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.745849     Document Type: Article

References (23)

1. Niaudet P. Steroid-sensitive nephrotic syndrome in children. In: Avner ED, Harmon W, Niaudet P, editors. Paediatric nephrology. 5th edition. Lippincott Williams and Wilkins; Philadephia: 2004. p. 543-56
2. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev 2008;CD002290
3. Amery WK, Bruynseels JP. Levamisole, the story and the lessons. Int J Immunopharmacol 1992;14:481-6
4. Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S. Treatment of nephrotic syndrome with levamisole. J Pediatr 1980;96:490-3 (Pubitemid 10147552)
5. British Association for Paediatric Nephrology. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. Lancet 1991;337:1555-7
6. Dayal R, Prasad R, Mathur P, et al. Effect of levamisole on T cell in minimal change nephrotic syndrome. Indian Pediatr 1988;25:1184-7 (Pubitemid 19041626)
7. Dayal U, Dayal AK, Shastry JC, Raghupathy P. Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children. Nephron 1994;66:408-12 (Pubitemid 24083584)
8. Drachman R, Schlesinger M, Alon U, et al. Immunoregulation with levamisole in children with frequently relapsing steroid responsive nephrotic syndrome. Acta Paediatr Scand 1988;77:721-6
9. Niaudet P, Drachman R, Gagnadoux MF, Broyer M. Treatment of idiopathic nephrotic syndrome with levamisole. Acta Paediatr Scand 1984;73:637-41 (Pubitemid 14030654)
10. Gruppen M, Merkus M, Davin J. Levamisole in steroid-sensitive nephrotic syndrome (SSNS): an international multicenter doubleblind randomized trial: the last news [abstract]. Pediatr Nephrol 2006;21:1531
11. European Medicines Agency. Reflection paper: formulations of choice for the paediatric population. EMEA/CHMP/ PEG/194810/2005, 2005
12. Thomson SA, Tuleu C, Wong IC, et al. Minitablets: new modality to deliver medicines to preschool-aged children. Pediatrics 2009;123:e235-8
13. Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA. Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases. Expert Opin Drug Deliv 2012;9:303-23
14. European Medicines Agency. Draft: Guideline on pharmaceutical development of medicines for paediatric use. EMA/CHMP/QWP/180157/2011, 2011
15. Yin HS, Mendelsohn AL, Wolf MS, et al. Parents' medication administration errors: role of dosing instruments and health literacy. Arch Pediatr Adolesc Med 2010;164:181-6
16. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007;4:37-45 (Pubitemid 46117485)
17. Pawar S, Kumar A. Issues in the formulation of drugs for oral use in children: role of excipients. Paediatr Drugs 2002;4:371-9 (Pubitemid 34651926)
18. Steffensen GK, Pachai A, Pedersen SE. Peroral drug administration to children - are there any problems? Ugeskr Laeger 1998;160:2249-52 (Pubitemid 128518440)
19. Salunke S, Hempenstall J, Kendall R, et al. European Paediatric Formulation Initiative's (EuPFI) 2nd conference commentary - formulating better medicines for children. Int J Pharm 2011;419:235-9
20. Spomer N, Klingmann V, Stoltenberg I, et al. Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child 2012;97(3):283-6
21. Chiappetta DA, Carcaboso AM, Bregni C, et al. Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance. AAPS PharmSciTech 2009;10:1-6
22. Fu LS, Shien CY, Chi CS. Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage. Nephron Clin Pract 2004;97:c137-41
23. European Medicines Agency. Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev 1/Corr, 2012